First Manhattan’s NovoCure NVCR Stock Holding History

First Manhattan’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-57	Closed	-$4.18K	–	1646
2022 Q4	$4.18K	Buy	+57	New	+$4.29K	﹤0.01%	1439

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Nordwand Advisors Radnor, Pennsylvania $572M AUM 23.09% 1-Year Est. Return

First Manhattan's NVCR Position: Q1 2023 in Review

First Manhattan sold out of NovoCure (NVCR) in Q1 2023, closing a stake of 57 shares — an estimated $4.18K sold.

First Manhattan first reported a position in NVCR in Q4 2022 and held it in 1 quarter. The position peaked at $4.18K in Q4 2022. 295 funds tracked by Wall St. Rank hold NVCR as of Q1 2023.

First Manhattan reported no remaining NovoCure position as of Q1 2023 after selling out during the quarter.
First Manhattan sold 57 NovoCure shares in Q1 2023, an estimated $4.18K.
First Manhattan first reported a position in NovoCure in Q4 2022 and held it in 1 quarter.
First Manhattan's NovoCure position peaked at $4.18K in Q4 2022.
295 funds tracked by Wall St. Rank held NovoCure as of Q1 2023.

Based on First Manhattan's 13F filing for Q1 2023, filed 15 May 2023.